Shankar T P, Solomon S S, Duckworth W C, Jerkins T, Iyer R S, Bobal M A
Department of Medicine, VA Medical Center, Memphis, Tennessee.
Horm Metab Res. 1988 Sep;20(9):579-83. doi: 10.1055/s-2007-1010889.
Patients with cirrhosis of the liver often have insulin resistance and elevated circulating growth hormone levels. This study was undertaken (a) to evaluate glucose intolerance, insulin resistance and abnormal growth hormone secretion and (b) to determine if GH suppression improves insulin resistance. Glucose tolerance tests (GTT), intravenous insulin tolerance tests (IVITT), arginine stimulation tests (AST) and glucose clamp studies before and during GH suppression with somatostatin were performed in a group of patients with alcohol-induced liver cirrhosis. During GTT cirrhotic subjects had a 2-hour plasma glucose of 200 +/- 9.8 ng/dl (N = 14) compared to 128 +/- 8.0 ng/dl in normal controls (N = 15), P less than 0.001. Basal GH was elevated in cirrhotic patients and in response to arginine stimulation reached a peak of 17.0 +/- 5.4 ng/ml (N = 7), compared to a peak of 11.3 +/- 1.8 ng/ml in 5 normal controls (P = NS). During IVITT patients with cirrhosis had a glucose nadir of 60.0 +/- 4.0 mg/dl (N = 9), compared to 29.0 +/- 7.0 mg/dl in controls (N = 5), P less than 0.001. Peak GH levels during IVITT were not significantly different in cirrhotics and controls. Glucose utilization rates in 4 patients with cirrhosis of the liver before somatostatin mediated GH suppression was 3.1 +/- 0.5 mg/kg/min and 6.5 +/- 1.5 mg/kg/min during somatostatin infusion, P less than 0.025. We conclude that patients with alcohol induced cirrhosis have sustained GH elevations resulting in insulin resistance which improves after GH suppression.
肝硬化患者常存在胰岛素抵抗且循环生长激素水平升高。本研究旨在:(a)评估葡萄糖耐量异常、胰岛素抵抗及生长激素分泌异常;(b)确定生长激素抑制是否能改善胰岛素抵抗。对一组酒精性肝硬化患者在使用生长抑素抑制生长激素前后进行了葡萄糖耐量试验(GTT)、静脉胰岛素耐量试验(IVITT)、精氨酸刺激试验(AST)及葡萄糖钳夹研究。在GTT期间,肝硬化受试者2小时血浆葡萄糖为200±9.8ng/dl(n = 14),而正常对照组为128±8.0ng/dl(n = 15),P<0.001。肝硬化患者基础生长激素升高,精氨酸刺激后峰值达17.0±5.4ng/ml(n = 7),而5名正常对照组峰值为11.3±1.8ng/ml(P = 无显著性差异)。在IVITT期间,肝硬化患者葡萄糖最低点为60.0±4.0mg/dl(n = 9),对照组为29.0±7.0mg/dl(n = 5),P<0.001。IVITT期间肝硬化患者和对照组的生长激素峰值无显著差异。4例肝硬化患者在生长抑素介导的生长激素抑制前葡萄糖利用率为3.1±0.5mg/kg/min,生长抑素输注期间为6.5±1.5mg/kg/min,P<0.025。我们得出结论,酒精性肝硬化患者生长激素持续升高导致胰岛素抵抗,生长激素抑制后胰岛素抵抗改善。